ゼリア新薬工業の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2024/05/02 | 2,102 | 2,130 | 2,098 | 2,119 | +21 | +1% | 58,300 |
2024/05/01 | 2,082 | 2,106 | 2,075 | 2,098 | +5 | +0.2% | 34,400 |
2024/04/30 | 2,076 | 2,099 | 2,056 | 2,093 | +34 | +1.7% | 52,100 |
2024/04/26 | 2,063 | 2,064 | 2,033 | 2,059 | +11 | +0.5% | 31,400 |
2024/04/25 | 2,067 | 2,072 | 2,044 | 2,048 | -15 | -0.7% | 43,500 |
2024/04/24 | 2,058 | 2,072 | 2,056 | 2,063 | +6 | +0.3% | 26,900 |
2024/04/23 | 2,056 | 2,065 | 2,047 | 2,057 | -1 | ±0% | 17,900 |
2024/04/22 | 2,035 | 2,061 | 2,035 | 2,058 | +45 | +2.2% | 32,800 |
2024/04/19 | 2,039 | 2,039 | 1,996 | 2,013 | -28 | -1.4% | 49,900 |
2024/04/18 | 2,025 | 2,052 | 2,023 | 2,041 | +16 | +0.8% | 38,400 |
2024/04/17 | 2,060 | 2,060 | 2,025 | 2,025 | -38 | -1.8% | 50,900 |
2024/04/16 | 2,080 | 2,082 | 2,058 | 2,063 | -25 | -1.2% | 47,700 |
2024/04/15 | 2,090 | 2,090 | 2,076 | 2,088 | -4 | -0.2% | 31,400 |
2024/04/12 | 2,085 | 2,100 | 2,079 | 2,092 | +7 | +0.3% | 37,900 |
2024/04/11 | 2,078 | 2,093 | 2,071 | 2,085 | -13 | -0.6% | 35,000 |
2024/04/10 | 2,104 | 2,110 | 2,096 | 2,098 | +3 | +0.1% | 30,500 |
2024/04/09 | 2,105 | 2,105 | 2,085 | 2,095 | ±0 | ±0% | 38,900 |
2024/04/08 | 2,087 | 2,101 | 2,075 | 2,095 | +26 | +1.3% | 50,500 |
2024/04/05 | 2,048 | 2,069 | 2,038 | 2,069 | +10 | +0.5% | 39,900 |
2024/04/04 | 2,070 | 2,071 | 2,055 | 2,059 | -16 | -0.8% | 57,500 |
2024/04/03 | 2,075 | 2,084 | 2,056 | 2,075 | -11 | -0.5% | 47,500 |
2024/04/02 | 2,126 | 2,130 | 2,078 | 2,086 | -40 | -1.9% | 73,400 |
2024/04/01 | 2,146 | 2,156 | 2,120 | 2,126 | -6 | -0.3% | 58,200 |
2024/03/29 | 2,124 | 2,146 | 2,124 | 2,132 | +16 | +0.8% | 54,800 |
2024/03/28 | 2,161 | 2,161 | 2,116 | 2,116 | -63 | -2.9% | 99,300 |
2024/03/27 | 2,170 | 2,192 | 2,170 | 2,179 | +13 | +0.6% | 130,700 |
2024/03/26 | 2,164 | 2,184 | 2,148 | 2,166 | -10 | -0.5% | 83,300 |
2024/03/25 | 2,190 | 2,205 | 2,176 | 2,176 | -27 | -1.2% | 100,600 |
2024/03/22 | 2,210 | 2,210 | 2,188 | 2,203 | +14 | +0.6% | 49,600 |
2024/03/21 | 2,212 | 2,213 | 2,183 | 2,189 | -8 | -0.4% | 87,500 |
2024/03/19 | 2,181 | 2,200 | 2,176 | 2,197 | +10 | +0.5% | 46,600 |
2024/03/18 | 2,176 | 2,194 | 2,170 | 2,187 | +6 | +0.3% | 92,200 |
2024/03/15 | 2,124 | 2,192 | 2,124 | 2,181 | +57 | +2.7% | 138,600 |
2024/03/14 | 2,119 | 2,129 | 2,102 | 2,124 | +16 | +0.8% | 44,100 |
2024/03/13 | 2,122 | 2,128 | 2,099 | 2,108 | -14 | -0.7% | 46,100 |
2024/03/12 | 2,134 | 2,134 | 2,090 | 2,122 | -12 | -0.6% | 48,600 |
2024/03/11 | 2,138 | 2,149 | 2,108 | 2,134 | -20 | -0.9% | 70,500 |
2024/03/08 | 2,137 | 2,167 | 2,123 | 2,154 | +15 | +0.7% | 83,900 |
2024/03/07 | 2,172 | 2,172 | 2,131 | 2,139 | -14 | -0.7% | 57,400 |
2024/03/06 | 2,115 | 2,168 | 2,115 | 2,153 | +34 | +1.6% | 125,200 |
2024/03/05 | 2,144 | 2,144 | 2,107 | 2,119 | -28 | -1.3% | 53,700 |
2024/03/04 | 2,144 | 2,169 | 2,125 | 2,147 | +30 | +1.4% | 98,100 |
2024/03/01 | 2,125 | 2,130 | 2,107 | 2,117 | -3 | -0.1% | 38,500 |
2024/02/29 | 2,127 | 2,127 | 2,108 | 2,120 | +6 | +0.3% | 55,500 |
2024/02/28 | 2,130 | 2,141 | 2,111 | 2,114 | -17 | -0.8% | 48,200 |
2024/02/27 | 2,145 | 2,147 | 2,125 | 2,131 | -18 | -0.8% | 41,300 |
2024/02/26 | 2,145 | 2,166 | 2,140 | 2,149 | ±0 | ±0% | 61,700 |
2024/02/22 | 2,176 | 2,176 | 2,138 | 2,149 | -6 | -0.3% | 69,100 |
2024/02/21 | 2,178 | 2,180 | 2,152 | 2,155 | -23 | -1.1% | 45,000 |
2024/02/20 | 2,178 | 2,192 | 2,172 | 2,178 | +5 | +0.2% | 41,700 |
1~
50
件表示中 / 3448件
類似銘柄と比較する
現在ご覧いただいている「ゼリア新薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
ゼリア新薬 | 211,900円 | +6.8% | +18.7% | 2.08% | 13.34倍 | 1.23倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
杏林製薬 | 183,900円 | +2.6% | +11.5% | 2.83% | 21.56倍 | 0.84倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
鳥居薬 | 396,000円 | +7.3% | +16.8% | 3.03% | 23.69倍 | 0.93倍 |
|
JT傘下。自社製品の腎・透析、アレルゲン等の開発強化。柱の抗HIV薬の販売権喪失が直撃 |
JCRファーマ | 80,600円 | +32.2% | +84.6% | 2.48% | 13.78倍 | 1.79倍 |
|
ヒト成長ホルモン製剤が主力、バイオ後続品も成長。希少疾病のバイオ新薬開発にも取り組む |
栄研化 | 202,700円 | -6.4% | -45.4% | 2.52% | 23.07倍 | 1.40倍 |
|
臨床検査薬大手。便潜血検査試薬(FIT)はシェア7割弱。尿検査(ウロ)、遺伝子検査も育成 |
市場注目の銘柄
チャート関連のコラム